Related Experiment Video
Updated: Apr 7, 2026

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery
Published on: June 23, 2011
Targeting the gastrointestinal tract to develop novel therapies for HIV
R K Reeves1, A Burgener2,3,4, N R Klatt5,6
1Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Abstract:
Despite the use of antiretroviral therapy (ART), which delays and/or prevents AIDS pathogenesis, human immunodeficiency virus (HIV)-infected individuals continue to face increased morbidities and mortality rates compared with uninfected individuals. Gastrointestinal (GI) mucosal dysfunction is a key feature of HIV infection, and is associated with mortality. In this study, we review current knowledge about mucosal dysfunction in HIV infection, and describe potential avenues for therapeutic targets to enhance mucosal function and decrease morbidities and mortalities in HIV-infected individuals.
Related Concept Videos
Microorganisms in Medicine and Therapeutics
Targeted Cancer Therapies
There are several types of targeted therapies against...
Pharmacogenomics: Identification of New Drug Targets
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
What is Monogastric Digestion?

